Analysis10k / Blog
EN한국어ES
Company Snapshot · LLY

Eli Lilly (LLY): What This Company Actually Does

The short answer

Eli Lilly develops and manufactures its own diabetes and obesity injectables, Mounjaro and Zepbound, in company-owned factories, then sells them to patients worldwide — and those two drugs alone now make up 56% of total revenue.

Share price
$1351.12
FY2025 revenue
$65.18B
FY2025 revenue growth
+44.7%
Mounjaro+Zepbound share
56.0%

How Eli Lilly makes money

Eli Lilly develops and manufactures its own drugs—most notably diabetes and obesity injectables Mounjaro and Zepbound—in company-owned factories, then sells them to patients and hospitals worldwide and collects the payment.

R&D
20%+ of revenue reinvested
→
ELI LILLY
In-house manufacturing
Mounjaro, Zepbound, and more
→
3 wholesalers
McKesson, Cencora,
Cardinal Health
→
Pharmacies/hospitals → patients
Paid by patients
and insurers

Simplified. Profit flows back into R&D and new manufacturing capacity. Source: 10-K FY2025, p.7, 51.

Where the revenue comes from

Revenue by therapeutic area — FY2025

Cardiometabolic health (obesity, diabetes)
74.0%
Oncology
14.4%
Immunology
8.1%
Neuroscience
2.1%
Other
1.4%

Cardiometabolic health was 57.6% of revenue in 2023 and has climbed to 74.0% by 2025 — concentration in Mounjaro and Zepbound keeps deepening each year. Source: 10-K FY2025, p.64–65 (Note 2).

Reading the geography International revenue is 33% of the total, exposing Lilly to euro, yen, and yuan swings, but the U.S. still dominates at 66.7%.

Customers and competitors

Patients are the end users, but payment actually flows through three U.S. pharmaceutical wholesalers—McKesson, Cencora, and Cardinal Health—each representing a meaningful share of revenue, though none individually exceeds 10% per company disclosure.

  • Novo Nordisk — the dominant rival in GLP-1 obesity and diabetes drugs (Ozempic, Wegovy); the market is effectively split between these two companies.
  • Pfizer — developing an oral obesity pill that would compete directly with Lilly's own oral GLP-1 candidate, orforglipron, currently under regulatory review.
  • Amgen — a later entrant developing next-generation obesity injectables, including MariTide.

Source: 10-K FY2025, p.7.

The metric that matters most in this sector

Whether Lilly's recent growth reflects genuine business expansion or concentration risk in just two drugs is the clearest read on this company. The share of revenue from Mounjaro and Zepbound combined shows exactly how far that concentration has gone.

Mounjaro + Zepbound revenue as a share of total

YearMounjaro + Zepbound revenueShare of total revenue
2023$5,339M15.6%
2024$16,466M36.6%
2025$36,508M56.0%

Source: 10-K FY2025, p.64 (product revenue), p.32 (risk factors: "Mounjaro and Zepbound accounted for 56 percent of our total revenues in 2025").

Worth watching This concentration cuts both ways — it has powered explosive growth so far, but it also means the entire company's fortunes now ride on two drugs facing intensifying competition, pricing pressure, and litigation.

Leadership and ownership

CEO David Ricks has led the company since 2017 and holds both the chair and president titles. The founding family no longer runs operations, but Lilly Endowment Inc.—a charitable foundation created by the founding family—remains the largest shareholder at 9.8%, followed by Vanguard (8.6%), BlackRock (6.8%), and PNC as trustee for employee compensation plans (5.4%).

Source: DEF 14A 2026, p.41–42.

Capital returns

Lilly paid $6.00 per share in dividends in 2025 and raised its quarterly dividend to $1.73 ($6.92 annualized) starting in Q1 2026, a payout ratio of roughly 26% of net income. Buybacks have grown every year—from $750M in 2023 to $2.5B in 2024 to $4.1B in 2025—out of a $15B program with $10.9B remaining. Repurchased shares are retired immediately, and shares outstanding actually declined slightly from 900.2M in 2023 to 897.3M in 2025, meaning the buybacks haven't yet been offset by new stock-based compensation issuance.

Source: 10-K FY2025, p.51–52.

How this company could fail

Failure scenario If Novo Nordisk or an oral obesity-pill competitor launches a cheaper, more convenient alternative and patients switch en masse, more than half of Lilly's revenue could be at risk at once.
  • Extreme product concentration — Mounjaro and Zepbound alone are 56% of revenue, and the top six products together are 82% (2025). A patent challenge or intensified competition hits the whole company at once.
  • Drug-pricing policy risk — a November 2025 preliminary agreement with the U.S. government on Medicaid pricing requires Lilly to offer discounted obesity-drug access to Medicaid patients starting July 2026. Expanding government pricing pressure would compress margins.
  • Product litigation risk — since August 2023, multiple lawsuits alleging gastrointestinal side effects and optic neuropathy (NAION) tied to Mounjaro, Trulicity, and Zepbound are proceeding through two federal multidistrict litigations — targeting the exact products driving the company's growth.

Source: 10-K FY2025, p.32–33 (concentration), p.32, 46 (pricing), p.90 (litigation).

Five-year financials

Revenue: 2021 28,318, 2022 28,541, 2023 34,124, 2024 45,043, 2025 65,179. Free cash flow: 2021 5,951, 2022 5,230, 2023 792, 2024 3,760, 2025 8,97228,3185,951202128,5415,230202234,124792202345,0433,760202465,1798,9722025
RevenueFree cash flowSame figures as the table below.
$ millions unless noted
20212022202320242025
Revenue28,31828,54134,12445,04365,179
YoY growth—+0.8%+19.6%+32.0%+44.7%
Operating income*6,3577,1276,45712,89926,302
Operating margin22.4%25.0%18.9%28.6%40.4%
Free cash flow5,9515,2307923,7608,972
Total debt16,88516,23925,22533,64442,503
Worth watching * Lilly doesn't disclose a formal operating-income line item; this figure is calculated directly from revenue minus cost of goods sold, R&D, SG&A, acquired IPR&D, and impairment/restructuring charges. 2023's free-cash-flow collapse to $792M reflects a sharp jump in capital spending on new manufacturing capacity, not a business problem — FCF recovered strongly in 2024 and 2025 as that capacity came online.

Sources: 10-K FY2021, FY2022, FY2025 (income statement p.57, balance sheet p.58–59, cash flow statement p.60–61). FCF = operating cash flow − capex.

What we still don't know

  • When and under what conditions orforglipron (the oral obesity pill) will actually receive FDA approval can't be determined from this filing alone — check recent earnings calls.
  • How much the November 2025 preliminary Medicaid pricing agreement will affect margins once finalized isn't quantified in the disclosure.
  • The potential financial exposure from the incretin-drug multidistrict litigation is not yet estimable and needs to be tracked in future quarterly filings' contingencies section.
Built from Eli Lilly's 10-K filings for fiscal years 2021–2025, its 10-Q filings, and its 2026 DEF 14A. This is a research summary, not investment advice — verify against the original filings before acting.

Frequently asked questions

What does Eli Lilly do?

Eli Lilly develops and manufactures its own prescription drugs — most notably the diabetes and obesity injectables Mounjaro and Zepbound — in company-owned factories, then sells them worldwide through wholesalers to pharmacies and hospitals.

How concentrated is Eli Lilly's revenue in just two drugs?

Mounjaro and Zepbound combined made up 56% of total revenue in 2025, up from 36.6% in 2024 and just 15.6% in 2023 — a concentration that has deepened every year as those two drugs have driven the company's growth.

How fast is Eli Lilly growing?

Revenue grew 44.7% in 2025 to $65.18 billion, following 32.0% growth in 2024 — among the fastest growth rates of any large pharmaceutical company, driven almost entirely by Mounjaro and Zepbound demand.